|
|
||
 |
| U.S.-based biopharmaceutical company NeoImmuneTech's CEO Yang Se-hwan speaks during the firm's IPO press conference held at the Conrad Seoul on Yeouido in the capital, Monday. Founded in 2014, the T-cell-focused company is dedicated to the discovery of novel immune-therapeutics in cooperation with major global pharmaceutical companies. The firm's stock allotment subscription period is for two days in early May and it's expected to make its KOSDAQ debut in mid-March. Courtesy of NeoImmuneTech |
Korea to create world's largest chip manufacturing complex 
Professor accuses school of covering up rape allegations 
Designating Han River parks as alcohol free zones causes controversy 
Migration for the benefit of all 
Israel steps up Gaza offensive, kills senior Hamas figures 
Myanmar beauty queen takes up arms against military junta 
KOSPI, large-cap cryptocurrencies teeter on US inflation fears 
Migrant workers work 50 hours per week on average: report 
'US intel chief's open visit to South Korea targets China, North Korea' 
Tesla to stop accepting bitcoin for car payments 
![[INTERVIEW] For Gong Seung-yeon, 'Aloners' marks a new beginning](http://img.koreatimes.co.kr/upload/thumbnailV2/f6961dc3920f4ce1bac18ab44ba0b37d.jpg/dims/resize/178/optimize)
